Migraine prevalence, disease burden, and the need for preventive therapy.
about
Period prevalence of self-reported headache in the general population in Germany from 1995-2005 and 2009: results from annual nationwide population-based cross-sectional surveysDiagnosing migraine in research and clinical settings: the validation of the Structured Migraine Interview (SMI)Reduction in perceived stress as a migraine trigger: testing the "let-down headache" hypothesisSumatriptan plus naproxen for the treatment of acute migraine attacks in adultsSelective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.Spinal rehabilitative exercise and manual treatment for the prevention of migraine attacks in adultsZolmitriptan for acute migraine attacks in adultsDiclofenac with or without an antiemetic for acute migraine headaches in adultsAspirin with or without an antiemetic for acute migraine headaches in adultsParacetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adultsIbuprofen with or without an antiemetic for acute migraine headaches in adultsSumatriptan plus naproxen for acute migraine attacks in adultsSumatriptan (intranasal route of administration) for acute migraine attacks in adultsSumatriptan (subcutaneous route of administration) for acute migraine attacks in adultsDiclofenac with or without an antiemetic for acute migraine headaches in adultsSumatriptan (oral route of administration) for acute migraine attacks in adultsSumatriptan (rectal route of administration) for acute migraine attacks in adultsZolmitriptan for acute migraine headaches in adultsIbuprofen with or without an antiemetic for acute migraine headaches in adultsSumatriptan for acute migraine headaches in adultsDiclofenac with or without an antiemetic for acute migraine headaches in adultsSumatriptan (all routes of administration) for acute migraine attacks in adults: an overview of Cochrane reviewsSumatriptan plus naproxen for acute migraine headaches in adultsNaproxen with or without antiemetic for acute migraine headaches in adultsAspirin with or without an antiemetic for acute migraine headaches in adultsRizatriptan for acute migraine headaches in adultsParacetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adultsTricyclic antidepressants and headaches: systematic review and meta-analysisEvidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache SocietyEvidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache SocietyClinical features and associated syndromes of mal de debarquementThe FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reportsRizatriptan for acute migraine headaches in adultsRecent advances in migraine therapyNew players in the preventive treatment of migraineGuideline for primary care management of headache in adultsTreatment of Chronic Migraine with Focus on Botulinum NeurotoxinsHeadache and Tremor: Co-occurrences and Possible AssociationsNeurological diseases and painA review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
P2860
Q21146956-853AA7F5-4C4A-4151-98CB-31C6A27BFABCQ21261405-479D65A2-54D9-40BD-92D4-C0F1B7D789DAQ23920101-89DA6040-E394-4037-BBF4-9305BBC87D1AQ24185878-0DF151F8-0C0B-4693-92C6-A55351F7ADC6Q24186656-733F3EFC-EF99-4271-BFC1-7D133652606CQ24188086-5FDABAD0-0914-4DA7-B3BA-0E985879126EQ24194592-EDDA439E-C29B-441F-9CE0-4B45330B17C2Q24197666-13805368-612C-4178-A491-413FDBDD4B2DQ24197721-A041150E-713C-4CF1-B91A-9B87884FFC7DQ24197826-AC20E98B-5312-4040-8CA8-1129F545E73FQ24197974-B1AA10B8-F11C-4092-AEAC-C5D3231FBD54Q24202970-62193EDB-53DF-4588-9EE8-46ECE811CD9DQ24203640-2E759DD1-21EB-4102-8A28-5197EE2EFE00Q24203684-1E0FB453-BBCF-4CE5-91AA-CD06184A4ABFQ24203701-E821E36F-33ED-40F1-B595-7D3626EFFB5FQ24203707-AF626668-D1F2-4B5B-BF9F-0E6750BF2C71Q24203726-187FCAE1-AC26-47E1-9BC2-DC0A05828361Q24234412-2DC452D3-8887-499F-8DE4-E7BD0F9D0611Q24234446-1328C136-ED29-40C7-9AD1-DDB5C4269877Q24234506-DA8840F6-5CAB-4F4F-AA56-62B901F4EB8EQ24234848-879CE735-CA32-4054-986F-C7643454B03BQ24235029-8F3E2C31-3273-48B9-B755-5C43A847021FQ24235044-6B4C3650-844A-4456-B805-A928439F1D25Q24235583-54C34F4C-1781-4742-974E-4EFF9C2A684CQ24235987-028537C2-2C48-48BB-B5A4-BDBF5658FABFQ24236184-C3CD0620-C084-468C-B6DB-A8F4AE7BDE35Q24236410-90A2E30D-93B4-4D9B-BAA0-7C2FBD2FB4D8Q24629493-0A1B0710-6AC7-4E11-B01D-5F792CF5FDF6Q24633523-5959405B-CEC3-4FAC-A490-971BA6B0689CQ24633546-7F7E4987-2C66-438C-940F-FBF957C1E57AQ24649080-528C176D-F6B5-45D5-A56E-0D9DBC084B4DQ24684333-10B87EFD-714E-4864-A24C-4D63E6546DC0Q26471366-022307E0-F535-48EE-BBEA-4F03F112A5CFQ26743537-E59843ED-EA42-41EC-BC7E-E8578D7BE152Q26778185-3CC9637E-7C49-4B6B-A2DD-912A4ED5A682Q26798397-31A86E87-CDDE-4101-BBA3-801744D70ACAQ26799906-B7B3A0C9-62BB-4BCF-9D0F-D9DAEFB1B6ACQ26801534-A1F116B5-90E8-4E35-B859-CB214831FBC0Q26822891-E4B3AB7D-D7EB-419E-901F-11CA7AB34A0FQ26823673-C9469298-DB63-43E6-99E7-5BE30E0D6F46
P2860
Migraine prevalence, disease burden, and the need for preventive therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Migraine prevalence, disease burden, and the need for preventive therapy.
@en
Migraine prevalence, disease burden, and the need for preventive therapy.
@nl
type
label
Migraine prevalence, disease burden, and the need for preventive therapy.
@en
Migraine prevalence, disease burden, and the need for preventive therapy.
@nl
prefLabel
Migraine prevalence, disease burden, and the need for preventive therapy.
@en
Migraine prevalence, disease burden, and the need for preventive therapy.
@nl
P2093
P1433
P1476
Migraine prevalence, disease burden, and the need for preventive therapy.
@en
P2093
AMPP Advisory Group
W F Stewart
P304
P356
10.1212/01.WNL.0000252808.97649.21
P407
P577
2007-01-01T00:00:00Z